Autoimmune Hepatitis Supportive Care Protocol

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease where the immune system attacks liver cells. It can lead to cirrhosis and liver failure if not treated. The cause is unknown but involves genetic susceptibility and environmental triggers. Symptoms include fatigue, jaundice, abdominal discomfort, and joint pain. Some people have no symptoms until advanced disease.

CRITICAL: Autoimmune hepatitis requires immunosuppressive treatment. Standard therapy is corticosteroids (prednisone) often combined with azathioprine. This treatment induces remission in most patients and prevents progression to cirrhosis. Without treatment, AIH can be fatal. These supplements may provide supportive benefit but absolutely DO NOT replace immunosuppressive therapy. Regular monitoring of liver enzymes, autoantibodies, and liver function is essential. Work closely with a hepatologist or gastroenterologist.

* Vitamin D deficiency is very common in autoimmune hepatitis and other liver diseases. Studies show lower vitamin D levels correlate with more severe disease. Vitamin D has immunomodulatory effects that may help regulate the overactive immune response. Supplementing to achieve adequate levels (40-60 ng/mL) is reasonable.

* Omega-3 Fatty Acids have anti-inflammatory properties that may help reduce hepatic inflammation. They also support overall liver health.

* N-Acetyl Cysteine (NAC) is a precursor to glutathione, the liver's primary antioxidant. It supports the liver's detoxification capacity and protects against oxidative damage.

* Milk Thistle (Silymarin) has been used traditionally for liver support. It has antioxidant and possibly anti-fibrotic effects, though evidence in AIH specifically is limited.

* Probiotics support the gut-liver axis. An unhealthy gut microbiome can contribute to liver inflammation through increased intestinal permeability and bacterial products reaching the liver.

* Vitamin E is an antioxidant that has shown benefit in non-alcoholic liver disease. It may help reduce oxidative stress in AIH.

* Selenium supports glutathione peroxidase function. Selenium deficiency is common in chronic liver diseases.

Expected timeline: Immunosuppressive therapy typically shows improvement in liver enzymes within weeks to months. Supplements provide ongoing support. Vitamin D optimization takes 2-3 months. AIH management is lifelong.

Clinical Perspective

Autoimmune hepatitis: immune-mediated liver inflammation with interface hepatitis, hypergammaglobulinemia, autoantibodies (ANA, SMA, anti-LKM1, anti-SLA). Type 1 (ANA/SMA+, adult-onset), Type 2 (anti-LKM1+, pediatric/young adult). Diagnosis: elevated transaminases, increased IgG, positive autoantibodies, compatible histology, exclusion of viral hepatitis. Simplified diagnostic criteria or original scoring system. Often presents insidiously; may have acute presentation mimicking acute viral hepatitis.

CRITICAL: Standard treatment: prednisone (40-60mg taper) + azathioprine (1-2mg/kg). Remission (normalization ALT, IgG, histology) in 65-80%. Relapse common after treatment withdrawal (50-90%). Many require lifelong low-dose maintenance. Budesonide alternative in non-cirrhotics. Second-line: mycophenolate, tacrolimus. Monitor for steroid side effects, bone loss, infections. Transplant for decompensated cirrhosis or fulminant AIH. Supplements are ADJUNCTIVE - do not replace immunosuppression.

* Vitamin D (B-grade): VDR in hepatocytes and immune cells. Clinical study: deficiency common in AIH, correlates with disease activity (PMID: 25614184). Systematic review: vitamin D important in autoimmune liver diseases (PMID: 28371132). Target 40-60 ng/mL.

* Omega-3 Fatty Acids (C-grade): Anti-inflammatory; may reduce hepatic inflammation. Review: benefits in chronic liver diseases (PMID: 24965308). 2-3g EPA+DHA daily.

* NAC (C-grade): Glutathione precursor; hepatoprotective. Review: liver protection mechanisms (PMID: 23856586). 600-1200mg BID. Used in acetaminophen toxicity; general hepatoprotection.

* Milk Thistle (C-grade): Silymarin - flavonoid complex. Cochrane review: no clear benefit in liver disease trials, but generally safe (PMID: 20564545). 420-600mg daily.

* Probiotics (C-grade): Gut-liver axis modulation. Systematic review: may benefit liver diseases (PMID: 26999547). 20-50 billion CFU daily.

* Vitamin E (C-grade): Lipid-soluble antioxidant. PIVENS trial: benefit in NASH (PMID: 20427778). Less evidence for AIH specifically. 400-800 IU daily.

* Selenium (C-grade): Selenoproteins; glutathione peroxidase. Review: deficiency in liver diseases (PMID: 26073418). 100-200mcg daily.

Biomarker targets: ALT, AST (normalize for remission), IgG level, autoantibody titers, liver biopsy (if indicated), FibroScan for fibrosis assessment, vitamin D level.

Protocol notes: Don't delay immunosuppression - early treatment prevents fibrosis progression. Bone health: calcium + vitamin D mandatory with steroids. DXA at baseline if prolonged steroid use anticipated. Azathioprine: check TPMT before starting, monitor CBC. Vaccination: hepatitis A/B (before immunosuppression if possible), influenza, pneumococcal. Avoid live vaccines while immunosuppressed. Screen for overlap syndromes (PBC, PSC overlap). Drug-induced AIH (minocycline, nitrofurantoin, statins) - different course. Pregnancy considerations - azathioprine generally safe. Lifestyle: avoid alcohol, maintain healthy weight. Monitor for hepatocellular carcinoma in cirrhosis. Treatment endpoints: biochemical remission (normal ALT, IgG), histological remission. Treatment duration: minimum 2-3 years; often lifelong. Prognosis: good with treatment; survival approaches general population.

View All Protocols